The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020

被引:379
|
作者
Pizzato, Margherita [1 ,2 ]
Li, Mengmeng [3 ]
Vignat, Jerome [2 ]
Laversanne, Mathieu [2 ]
Singh, Deependra [2 ]
La Vecchia, Carlo [1 ]
Vaccarella, Salvatore [2 ]
机构
[1] Univ Milan, Dept Clin Sci & Community Hlth, I-20133 Milan, Italy
[2] Int Agcy Res Canc, Lyon, France
[3] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Canc Prevent, State Key Lab Oncol South China, Guangzhou, Peoples R China
来源
LANCET DIABETES & ENDOCRINOLOGY | 2022年 / 10卷 / 04期
关键词
UNITED-STATES; INCREASING INCIDENCE; POOLED ANALYSIS; NEW-CALEDONIA; TIME TRENDS; TASK-FORCE; IMPACT; RISK; OVERDIAGNOSIS; SURVIVAL;
D O I
10.1016/S2213-8587(22)00035-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Summary Background Thyroid cancer incidence rates have increased in many countries and settings; however, mortality rates have remained stable at lower rates. This epidemiological pattern has been largely attributed to an overdiagnosis effect. Timely evidence for the global epidemiological status is necessary to identify the magnitude of this problem and the areas mostly affected by it. We therefore aimed to provide an up-to-date assessment on the global distribution of thyroid cancer incidence and mortality rates in 2020. Methods We extracted age-standardised incidence and mortality rates per 100 000 person-years of thyroid cancer as defined by the International Classification of Diseases for Oncology 10th Revision (code C73), for 185 countries or territories by sex and 18 age groups (ie, 0-4, 5-9, ... , 80-84, and >= 85 years) from the GLOBOCAN database. Both incidence and mortality estimates were presented by country and aggregated across the 20 UN-defined world regions and according to the UN's four-tier Human Development Index (ie, low, medium, high, and very high) in 2020. Findings Globally, in 2020, the age-standardised incidence rates of thyroid cancer were 10 center dot 1 per 100 000 women and 3 center dot 1 per 100 000 men, and age-standardised mortality rates were 0 center dot 5 per 100 000 women and 0 center dot 3 per 100 000 men. In both sexes, incidence rates were five times higher in high and very high Human Development Index countries than in low and medium Human Development Index countries, whereas mortality rates were relatively similar across different settings. Incidence rates in women differed by more than 15 times across world regions, with the highest incidence rates being in the Federated States of Micronesia and French Polynesia (18 center dot 5 per 100 000 women), North America (18 center dot 4 per 100 000), and east Asia (17 center dot 8 per 100 000, with South Korea reaching 45 per 100 000). Mortality rates were less than one per 100 000 in most countries and in both sexes. South Korea had the highest incidence-to-mortality rate ratio in both sexes, followed by Cyprus and Canada. Interpretation The current thyroid cancer epidemiological landscape is strongly suggestive of a large effect of overdiagnosis in many countries and settings worldwide, confirming the relevance of thyroid cancer overdiagnosis as a global public health problem.
引用
收藏
页码:264 / 272
页数:9
相关论文
共 50 条
  • [1] Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Sung, Hyuna
    Ferlay, Jacques
    Siegel, Rebecca L.
    Laversanne, Mathieu
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    Bray, Freddie
    CA-A CANCER JOURNAL FOR CLINICIANS, 2021, 71 (03) : 209 - 249
  • [2] Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN
    Lyu Zhangyan
    Zhang Yu
    Sheng Chao
    Huang Yubei
    Zhang Qiang
    Chen Kexin
    中华医学杂志英文版, 2024, 137 (21)
  • [3] GLOBOCAN 1: Cancer incidence and mortality worldwide.
    Meijer, GA
    JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (02) : 164 - 164
  • [4] Global burden of thyroid cancer in 2022: Incidence and mortality estimates from GLOBOCAN
    Lyu, Zhangyan
    Zhang, Yu
    Sheng, Chao
    Huang, Yubei
    Zhang, Qiang
    Chen, Kexin
    CHINESE MEDICAL JOURNAL, 2024, 137 (21) : 2567 - 2576
  • [5] Estimates of melanoma incidence and mortality rates in Europe: Globocan 2008
    Forsea, Ana-Maria
    Geller, Alan
    Bailey, Elizabeth E.
    de Vries, Esther
    del Marmol, Veronique
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB144 - AB144
  • [6] Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN
    Morgan, Eileen
    Arnold, Melina
    Gini, A.
    Lorenzoni, V
    Cabasag, C. J.
    Laversanne, Mathieu
    Vignat, Jerome
    Ferlay, Jacques
    Murphy, Neil
    Bray, Freddie
    GUT, 2023, 72 (02) : 338 - 344
  • [7] Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Laversanne, Mathieu
    Sung, Hyuna
    Ferlay, Jacques
    Siegel, Rebecca L.
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    CA-A CANCER JOURNAL FOR CLINICIANS, 2024, 74 (03) : 229 - 263
  • [8] Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
    Bray, Freddie
    Ferlay, Jacques
    Soerjomataram, Isabelle
    Siegel, Rebecca L.
    Torre, Lindsey A.
    Jemal, Ahmedin
    CA-A CANCER JOURNAL FOR CLINICIANS, 2018, 68 (06) : 394 - 424
  • [9] Epidemiological landscape of esophageal cancer in Asia: Results from GLOBOCAN 2020
    Zhu, Hongcheng
    Wang, Zezhou
    Deng, Bingbin
    Mo, Miao
    Wang, Honggang
    Chen, Ke
    Wu, Haoxuan
    Ye, Ting
    Wang, Boyan
    Ai, Dashan
    Hao, Shennan
    Tseng, Ihsuan
    Zhao, Kuaile
    THORACIC CANCER, 2023, 14 (11) : 992 - 1003
  • [10] Modelling incidence and mortality cancer parameters with respect to GLOBOCAN 2020Age standardized world estimates
    Acquah, Joseph
    Bosson-Amedenu, Senyefia
    Eyiah-Bediako, Francis
    Buabeng, Albert
    Ouerfelli, Noureddine
    HELIYON, 2024, 10 (17)